Arcturus Therapeutics Holdings Inc. has an average 12-month price target of $29.50 from 13 analysts, with ratings ranging from sell to strong buy. Recent price targets have been lowered by some firms, reflecting cautious sentiment despite a moderate buy consensus. The company reported a quarterly loss and revenue below estimates, impacting investor outlook. Institutional investors hold over 94% of shares, showing strong backing despite mixed analyst views.
Cycurion received a Nasdaq delisting notice due to its stock price falling below the $1 minimum for 31 consecutive days. The company is appealing the decision, which allows its shares to keep trading on Nasdaq during the review. Cycurion is focused o...
TDb Split Corp. plans a 15-for-100 share split for its Class A shares, effective for shareholders of record on July 24, 2026, pending TSX approval. Following the split, shareholders will receive the same $0.05 monthly cash distribution per share, eff...
Law Offices of Howard G. Smith reminds investors of upcoming deadlines to file lead plaintiff motions in securities fraud class actions involving Badger Meter, PicS N.V., Verra Mobility, and Grail, Inc. The lawsuits allege these companies made mislea...
Assembli Events & Production is creating the Big Ten Conference's first fan activation at Fanatics Fest NYC, held July 16-19, 2026. This event marks the Big Ten as the first collegiate conference to join the premier sports fan festival, showcasing tr...
State Street posted strong Q2 results with earnings per share of $3.65, beating estimates and up from $2.53 last year. Quarterly revenue reached $4.05 billion, driven by a 17.2% rise in fee revenues and 18% growth in net interest income. Assets under...
